Curcumin and autoimmune disease

Advances in Experimental Medicine and Biology

Volumn 595, Issue , 2007, Pages 425-451

  Bright, John J ^a  

^a METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CHEMOKINE; CORTICOSTEROID; CURCUMIN; GAMMA INTERFERON; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; JANUS KINASE; LEFLUNOMIDE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHORYLASE KINASE; PROTEIN KINASE B; SALAZOSULFAPYRIDINE; STAT PROTEIN; STEROID; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CROHN DISEASE; CURCUMA LONGA; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MULTIPLE SCLEROSIS; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 84934437976     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-46401-5_19     Document Type: Review

References (166)

1. C. A. Janeway, Jr., The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 13, 11 (1992).
2. I. J. Crane and J. V. Forrester, Th1 and Th2 lymphocytes in autoimmune disease. Crit Rev Immunol 25, 75 (2005).
3. T. Tsubata, B cell abnormality and autoimmune disorders. Autoimmunity 38, 331 (2005).
4. J. J. Bright, C. Du, M. Coon, S. Sriram, and S. J. Klaus, Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: An effect of the novel anti-inflammatory drug lisofylline. J Immunol 161, 7015 (1998).
5. C. Natarajan and J. J. Bright, Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J Immunol 168, 6506 (2002).
6. P. Friedl, A. T. den Boer, and M. Gunzer, Tuning immune responses: Diversity and adaptation of the immunological synapse. Nat Rev Immunol 5, 532 (2005).
7. M. Kronenberg, Self-tolerance and autoimmunity. Cell 65, 537 (1991).
8. S. Anderton, C. Burkhart, B. Metzler, and D. Wraith, Mechanisms of central and peripheral T-cell tolerance: Lessons from experimental models of multiple sclerosis. Immunol Rev 169, 123 (1999).
9. A. W. Goldrath and S. M. Hedrick, Central tolerance matters.[comment]. Immunity 23, 113 (2005).
10. E. Thorsby and B. A. Lie, HLA associated genetic predisposition to autoimmune diseases: Genes involved and possible mechanisms. Transplant Immunol 14, 175 (2005).
11. S. G. Sukkar and E. Rossi, Oxidative stress and nutritional prevention in autoimmune rheumatic diseases. Autoimmun Rev 3, 199 (2004).
12. S. M. Rates, Plants as source of drugs. Toxicon 39, 603 (2001).
13. M. M. Chan, C. T. Ho, and H. I. Huang, Effects of three dietary phytochemicals from tea, rosemary and turmeric on inflammation-induced nitrite production. Cancer Lett 96, 23 (1995).
14. Y. Surh, Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat Res. 428, 305 (1999).
15. R. B. Arora, V. Kapoor, N. Basu, and A. P. Jain, Anti-inflammatory studies on Curcuma longa (turmeric). Indian J Med Res. 59, 1289 (1971).
16. D. Chandra and S. S. Gupta, Anti-inflammatory and anti-arthritic activity of volatile oil of Curcuma longa (Haldi). Indian J Med Res 60, 138 (1972).
17. N. Ghatak and N. Basu, Sodium curcuminate as an effective anti-inflammatory agent. Indian J Exp Biol 10, 235 (1972).
18. A. Mukhopadhyay, N. Basu, N. Ghatak, and P. K. Gujral, Anti-inflammatory and irritant activities of curcumin analogues in rats. Agents Actions 12, 508 (1982).
19. R. C. Srimal and B. N. Dhawan, Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol 25, 447 (1973).
20. H. P. Ammon, H. Safayhi, T. Mack, and J. Sabieraj, Mechanism of antiinflammatory actions of curcumine and boswellic acids. J Ethanopharmacol 38, 113 (1993).
21. A. C. Reddy and B. R. Lokesh, Studies on spice principles as antioxidants in the inhibition of lipid peroxidation of rat liver microsomes, Mol Cell Biochem. 111, 117 (1992).
22. M. N.Sreejayan Rao, Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm Pharmacol 46, 1013 (1994).
23. I. Brouet and H. Ohshima, Curcumin, an anti-tumour promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun 206, 533 (1995).
24. M. M. Chan, H. I. Huang, M. R. Fenton, and D. Fong, In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol 55, 1955 (1998).
25. F. Zhang, N. K. Altorki, J. R. Mestre, K. Subbaramaiah, and A. J. Dannenberg, Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 20, 445 (1999).
26. J. Y. Liu, S. J. Lin, and J. K. Lin, Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13- acetate in NIH 3T3 cells. Carcinogenesis 14, 857 (1993).
27. S. S. Kakar and D. Roy, Curcumin inhibits TPA induced expression of c-fos, c-jun and c-myc proto-oncogenes messenger RNAs in mouse skin. Cancer Lett 87, 85 (1994).
28. A. H. Conney, T. Lysz, T. Ferraro, T. F. Abidi, P. S. Manchand, J. D. Laskin, and M. T. Huang, Inhibitory effect of curcumin and some related dietary compounds on tumor promotion and arachidonic acid metabolism in mouse skin. Adv Enzyme Regul 31, 385 (1991).
29. Y. J. Surh, K. S. Chun, H. H. Cha, S. S. Han, Y. S. Keum, K. K. Park, and S. S. Lee, Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: Down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 480-481, 243 (2001).
30. P. Claeson, U. Pongprayoon, T. Sematong, P. Tuchinada, V. Reutrakul, P. Soontornsaratune, an W. C. Taylor, Non-phenolic linear diarylheptanoids from Curcuma xanthorrhiza. A novel type of topical anti-inflammatory agents: structure-activity relationship. Planta Med 62, 236 (1996).
31. P. Venkatesan and M. N. Rao, Structure-activity relationships for the inhibition of lipid peroxidation and the scavenging of free radicals by synthetic symmetrical curcumin analogues. J Pharm Pharmacol 52, 1123 (2000).
32. C. Natarajan and J. J. Bright, Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun 3, 59 (2002).
33. M. Srinivasan, Effect of curcumin on blood sugar as seen in a diabetic subject. Indian J Med Sci 26, 269 (1972).
34. P. S. Babu and K. Srinivasan, Influence of dietary curcumin and cholesterol on the progression of experimentally induced diabetes in albino rat. Mol Cell Biochem 152, 13 (1995).
35. A. Srivivasan, V. P. Menon, V. Periaswamy, and K. N. Rajasekaran, Protection of pancreatic beta-cell by the potential antioxidant bis-o-hydroxycinnamoyl methane, analogue of natural curcuminoid in experimental diabetes. J Pharm Pharm Sci 6, 327 (2003).
36. S. D. Deodhar, R. Sethi, and R. C. Srimal, Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 71, 632 (1980).
37. J. L. Funk, J. N. Oyarzo, J. B. Frye, G. Chen, R. C. Lantz, S. D. Jolad, A. M. Solyom, and B. N. Timmermann, Turmeric extracts containing curcuminoids prevent experimental rheumatoid arthritis. J Nat Prod 69, 351 (2006).
38. M. C. Heng, M. K. Song, J. Harker, and M. K. Heng, Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br J Dermatol 143, 937 (2000).
39. B. Bosman, Testing of lipoxygenase inhibitors, cyclooxygenase inhibitors, drugs with immunomodulating properties and some reference antipsoriatic drugs in the modified mouse tail test, an animal model of psoriasis, Skin Pharmacol 7, 324 (1994).
40. P. R. Holt, S. Katz, and R. Kirshoff, Curcumin therapy in inflammatory bowel disease, a pilot study. Dig Dis Sci 50, 2191 (2005).
41. K. Sugimoto, H. Hanai, K. Tozawa, T. Aoshi, M. Uchijima, T. Nagata, and Y. Koide, Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 123, 1912 (2002).
42. B. Salh, K. Assi, V. Templeman, K. Parhar, D. Owen, A. Gomez-Munoz, and K. Jacobson, Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physiol 285, G235 (2003).
43. Y. T. Jian, G. F. Mai, J. D. Wang, Y. L. Zhang, R. C. Luo, and Y. X. Fang, Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol 11, 1747 (2005).
44. G. Dean, How many people in the world have multiple sclerosis? Neuroepidemiology 13, 1 (1994).
45. S. Donoghue and C. Greenlees, Drugs in development for the treatment of multiple sclerosis, antigen non-specific therapies: An update. Expert Opin Investig Drugs 9, 167 (2000).
46. J. W. Prineas, R. O. Barnard, T. Revesz, E. E. Kwon, L. Sharer, and E. S. Cho, Multiple sclerosis. Pathology of recurrent lesions. Brain 116, 681 (1993).
47. B. D. Trapp, J. Peterson, R. M. Ransohoff, R. Rudick, S. Mork, and L. Bo, Axonal transection in the lesions of multiple sclerosis. [see comment]. N Engl J Med 338, 278 (1998).
48. C. S. Raine, Multiple sclerosis: Immunopathologic mechanisms in the progression and resolution of inflammatory demyelination. Res Publ Assoc Res Nerv Ment Dis 68, 37 (1990).
49. E. M. Frohman, M. K. Racke, and C. S. Raine, Multiple sclerosis: The plaque and its pathogenesis. N Engl J Med 354, 942 (2006).
50. J. J. Bright, B. F. Musuro, C. Du, and S. Sriram, Expression of IL-12 in CNS and lymphoid organs of mice with experimental allergic encephalitis. J Neuroimmunol 82, 22 (1998).
51. J. J. Bright, C. Du, and S. Sriram, Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis. J Immunol 162, 6255 (1999).
52. G. Muthian, H. P. Raikwar, C. Johnson, J. Rajasingh, A. Kalgutkar, L. J. Marnett, and J. J. Bright, COX-2 inhibitors modulate IL-12 signaling through JAK-STAT pathway leading to Th1 response in experimental allergic encephalomyelitis. J Clin Immunol 26, 73 (2006).
53. D. Devendra, E. Liu, and G. S. Eisenbarth, Type 1 diabetes: Recent developments. Br Med J 328, 750 (2004).
54. G. S. Eisenbarth, Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 314, 1360 (1986).
55. J. M. Barker, J. Yu, L. Yu, J. Wang, D. Miao, F. Bao, E. Hoffenberg, J. C. Nelson, P. A. Gottlieb, M. Rewers, and G. S. Eisenbarth, Autoantibody "subspecificity" in type 1 diabetes: Risk for organ-specific autoimmunity clusters in distinct groups. Diabetes Care 28, 850 (2005).
56. O. Kordonouri, R. Hartmann, D. Deiss, M. Wilms, and A. Gruters-Kieslich, Natural course of autoimmune thyroiditis in type 1 diabetes: Association with gender, age, diabetes duration, and puberty. Arch Dis Child 90, 411 (2005).
57. M. J. Franz, J. P. Bantle, C. A. Beebe, J. D. Brunzell, J.-L. Chiasson, A. Garg, L. A. Holzmeister, B. Hoogwerf, E. Mayer-Davis, A. D. Mooradian, J. Q. Purnell, M. Wheeler, American Diabetes, Association, Nutrition principles and recommendations in diabetes. Diabetes Care 27, S36 (2004).
58. G. S. Sidhu, H. Mani, J. P. Gaddipati, A. K. Singh, P. Seth, K. K. Banaudha, G. K. Patnaik, and R. K. Maheshwari, Curcumin enhances wound healing in streptozotocin induced diabetic rats and genetically diabetic mice. Wound Repair Regen 7, 362 (1999).
59. P. Suresh Babu and K. Srinivasan, Amelioration of renal lesions associated with diabetes by dietary curcumin in streptozotocin diabetic rats. Mol Cell Biochem 181, 87 (1998).
60. P. A. Kumar, P. Suryanarayana, P. Y. Reddy, and G. B. Reddy, Modulation of alpha-crystallin chaperone activity in diabetic rat lens by curcumin. Mol Vis 11, 561 (2005).
61. P. Suryanarayana, M. Saraswat, T. Mrudula, T.P. Krishna, K. Krishnaswamy, and G. B. Reddy, Curcumin and turmeric delay streptozotocin-induced diabetic cataract in rats. Invest Ophthalmol Vis Sci 46, 2092 (2005)
62. G. S. Firestein, Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol 11, S39 (2005).
63. C. J. Edwards and C. Cooper, Early environmental factors and rheumatoid arthritis. Clin Exp Immunol 143, 1 (2006).
64. E. M. Ruderman, Current and future pharmaceutical therapy for rheumatoid arthritis. Curr Pharm Des 11, 671 (2005).
65. A. Liacini, J. Sylvester, W. Q. Li, and M. Zafarullah, Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol 21, 251 (2002).
66. A. Liacini, J. Sylvester, W. Q. Li, W. Huang, F. Dehnade, M. Ahmad, an M. Zafarullah, Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes. Exp Cell Res 288, 208 (2003).
67. B. B. Aggarwal and S. Shishodia, Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: Reasoning for seasoning. Ann NY Acad Sci 1030, 434 (2004).
68. M. Shakibaei, G. Schulze-Tanzil, T. John, and A. Mobasheri, Curcumin protects human chondrocytes from IL-l1beta-induced inhibition of collagen type II and beta1-integrin expression and activation of caspase-3: An immunomorphological study, Ann Anat 187, 487 (2005).
69. S. Shishodia, G. Sethi, and B. B. Aggarwal, Curcumin: Getting back to the roots. Ann NY Acad Sci 1056, 206 (2005).
70. A. M. Bowcock, The genetics of psoriasis and autoimmunity. Annu Rev Genomics Hum Genet 6, 93 (2005).
71. S. Chow, C. Rizzo, L. Ravitskiy, and A. A. Sinha, The role of T cells in cutaneous autoimmune disease. Autoimmunity 38, 303 (2005).
72. J. G. Krueger and A. Bowcock, Psoriasis pathophysiology: Current concepts of pathogenesis. Ann Rheum Dis 64, 30 (2005).
73. J. Miquel, A. Bernd, J. M. Sempere, J. Diaz-Alperi, and A. Ramirez, The curcuma antioxidants: Pharmacological effects and prospects for future clinical use. A review. Arch Gerontol Geriatr 34, 37 (2002).
74. D. Shi, J. Das, and G. Das, Inflammatory bowel disease requires the interplay between innate and adaptive immune signals. Cell Res 16, 70 (2006).
75. E. Ricart, R. Panaccione, E. V. Loftus, Jr., W. J. Tremaine, W. S. Harmsen, A. R. Zinsmeister, and W. J. Sandborn, Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: A case-control study. Inflamm Bowel Dis 10, 207 (2004).
76. F. R. Byrne and J. L. Viney, Mouse models of inflammatory bowel disease. Curr Opin Drug Discov Devel 9, 207 (2006).
77. S. Ardizzone and G. Bianchi Porro, Biologic therapy for inflammatory bowel disease. Drugs 65, 2253 (2005).
78. E. Domenech, Inflammatory bowel disease: Current therapeutic options. Digestion 73, 67 (2006).
79. A. M. Feldman and D. McNamara, Myocarditis.[see comment]. N Engl J Med 343, 1388 (2000).
80. G. W. Dec, Jr., I. F. Palacios, J. T. Fallon, H. T. Aretz, J. Mills, D. C. Lee, and R. A. Johnson, Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Engl J Med 312, 885 (1985).
81. R. E. McCarthy 3rd, J. P. Boehmer, R. H. Hruban, G. M. Hutchins, E. K. Kasper, J. M. Hare, and K. L. Baughman, Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis.[see comment]. N Engl J Med 342, 690.
82. B. Lauer, M. Schannwell, U. Kuhl, B. E. Strauer, and H. P. Schultheiss, Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 35, 11 (2000).
83. A. L. Caforio, N. J. Mahon, F. Tona, and W. J. McKenna, Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis, pathogenetic and clinical significance. Eur J Heart Fail 4, 411 (2002).
84. D. Fairweather, Z. Kaya, G. R. Shellam, C. M. Lawson, and N. R. Rose, From infection to autoimmunity. J Autoimmun 16, 175 (2001).
85. Y. Furukawa, K. Kobuke, and A. Matsumori, Role of cytokines in autoimmune myocarditis and cardiomyopathy. Autoimmunity 34, 165 (2001).
86. M. Afanasyeva, D. Georgakopoulos, and N. R. Rose, Autoimmune myocarditis: Cellular mediators of cardiac dysfunction. Autoimmun Rev 3, 476 (2004).
87. W. Liu, W.-M. Li, C. Gao, and N.-L. Sun, Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. J Autoimmun 25, 258 (2005).
88. C. Nirmala and R. Puvanakrishnan, Protective role of curcumin against isoproterenol induced myocardial infarction in rats. Mol Cell Biochem 159, 85 (1996).
89. C. H. Yeh, T. P. Chen, Y. C. Wu, Y. M. Lin, and P. Jing Lin, Inhibition of NFkappaB activation with curcumin attenuates plasma inflammatory cytokines surge and cardiomyocytic apoptosis following cardiac ischemia/reperfusion. J Surg Res 125, 109 (2005).
90. C. H. Yeh, Y. M. Lin, Y. C. Wu, and P. J. Lin, Inhibition of NF-kappa B activation can attenuate ischemia/reperfusion-induced contractility impairment via decreasing cardiomyocytic proinflammatory gene up-regulation and matrix metalloproteinase expression. J Cardiovasc Pharmaco. 45, 301 (2005).
91. R. R. Singh, SLE: Translating lessons from model systems to human disease. Trends Immunol 26, 572 (2005).
92. R. Lyons, S. Narain, C. Nichols, M. Satoh, and W. H. Reeves, Effective use of autoantibody tests in the diagnosis of systemic autoimmune disease. Ann NY Acad Sci 1050, 217 (2005).
93. G. Nagy, A. Koncz, A. and A. Perl, T- and B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol 25, 123 (2005).
94. J. A. Croker and R. P. Kimberly, SLE: Challenges and candidates in human disease. Trends Immunol 26 , 580 (2005).
95. S. G. O'Neill and L. Schrieber, Immunotherapy of systemic lupus erythematosus. Autoimmun Rev 4, 395 (2005).
96. D. B. Drachman, Myasthenia gravis. N Engl J Med 330, 1797 (1994).
97. J. Lindstrom, D. Shelton, and Y. Fujii, Myasthenia gravis. Adv Immunol 42, 233 (1988).
98. K. Shigemoto, S. Kubo, N. Maruyama, N. Hato, H. Yamada, C. Jie, N. Kobayashi, K. Mominoki, Y. Abe, N. Ueda, and S. Matsuda, Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest. 116, 1016 (2006).
99. D. Asthana, Y. Fujii, G. E. Huston, and J. Lindstrom, Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis is mediated by IL-4 and antigen-specific T cell factors. Clin Immunol Immunopathol 67, 240 (1993).
100. G. X. Zhang, B. G. Xiao, M. Bakhiet, P. van der Meide, H. Wigzell, H. Link, and T. Olsson, Both CD4+ and CD8+ T cells are essential to induce experimental autoimmune myasthenia gravis. J Exp Med 184, 349 (1996).
101. L. Moiola, F. Galbiati, G. Martino, S. Amadio, E. Brambilla, G. Comi, A. Vincent, L. M. Grimaldi, and L. Adorini, IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. Eur J Immunol 28, 2487 (1998).
102. S. Sitaraman, D. W. Metzger, R. J. Belloto, . A. J. Infante, and K. A. Wall, Interleukin-12 enhances clinical experimental autoimmune myasthenia gravis in susceptible but not resistant mice. J Neuroimmunol 107, 73 (2000).
103. H. Tlaskalova-Hogenova, L. Tuckova, R. Stepankova, T. Hudcovic, L. Palova-Jelinkova, H. Kozakova, P. Rossmann, D. Sanchez, J. Cinova, T. Hrncir, M. Kverka, L. Frolova, H. Uhlig, F. Powrie, and P. Bland, Involvement of innate immunity in the development of inflammatory and autoimmune diseases. Ann NY Acad Sci 1051, 787 (2005).
104. D. N. Cook, D. S. Pisetsky, and D. A. Schwartz, Toll-like receptors in the pathogenesis of human disease. Nat Immunol 5, 975 92004).
105. G. Cheng and S. P. Schoenberger, CD40 signaling and autoimmunity. Curr Dir Autoimmun 5, 51 (2002).
106. H. S. Youn, S. I. Saitoh, K. Miyake, and D. H. Hwang, Inhibition of homodimerization of Toll-like receptor 4 by curcumin. Biochem Pharmacol 72, 62 (2006).
107. S. Kato, Y. Yuzawa, N. Tsuboi, S. Maruyama, Y. Morita, T. Matsuguchi, and S. Matsuo, Endotoxin-induced chemokine expression in murine peritoneal mesothelial cells: The role of toll-like receptor 4. J Am Soc Nephrol 15, 1289 (2004).
108. R. S. Liblau, S. M. Singer, and H. O. McDevitt, Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases.[see comment]. Immunol Today 16, 34 (1995).
109. B. Y. Kang, S. W. Chung, W. Chung, S. Im, S. Y. Hwang, and T. S. Kim, Inhibition of interleukin-12 production in lipopolysaccharide-activated macrophages by curcumin. Eur J Pharmacol 384, 191 (1999).
110. B. Y. Kang, Y. J. Song, K. M. Kim, Y. K. Choe, S. Hwang, and T. S. Kim, Curcumin inhibits Th1 cytokine profile in CD4+ T cells by suppressing interleukin-12 production in macrophages. Br J Pharmacol 128, 380 (1999).
111. M. Sospedra and R. Martin, Immunology of multiple sclerosis. Annu Rev Immunol 23, 683 (2005).
112. J. C. W. Edwards and G. Cambridge, B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 6, 394 (2006).
113. S. Hori, T. Takahashi, and S. Sakaguchi, Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol 81, 331 (2003).
114. L. A. Stephens, D. Gray, and S. M. Anderton, CD4+CD25+ regulatory T cells limit the risk of autoimmune disease arising from T cell receptor crossreactivity. Proc Natl Acad Sci USA 102, 17,418 (2005).
115. K. J. Hammond and D. I. Godfrey, NKT cells: Potential targets for autoimmune disease therapy? Tissue Antigens 59, 353 (2002).
116. S. Sharif, G. A. Arreaza, P. Zucker, Q. S. Mi, and T. L. Delovitch, Regulation of autoimmune disease by natural killer T cells. J Mol Med 80, 290 (2002).
117. R. M. Strieter, S. L. Kunkel, and R. C. Bone, Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med 21, S447 (1993).
118. H. Korner and J. D. Sedgwick, Tumour necrosis factor and lymphotoxin: Molecular aspects and role in tissue-specific autoimmunity. Immunol Cell Biol 74, 465 (1996).
119. F. Atzeni, M. Turiel, F. Capsoni, A. Doria, P. Meroni, and P. Sarzi-Puttini, Autoimmunity and anti-TNF-{alpha} agents. Ann NY Acad Sci 1051, 559 (2005).
120. K. Hosaka, J. Ryu, S. Saitoh, T. Ishii, K. Kuroda, and K. Shimizu, The combined effects of anti-TNFalpha antibody and IL-1 receptor antagonist in human rheumatoid arthritis synovial membrane. Cytokine 32, 263 (2005).
121. V. S. Yadav, K. P. Mishra, D. P. Singh, S. Mehrotra, and V. K. Singh, Immunomodulatory effects of curcumin. Immunopharmacol Immunotoxicol 27, 485 (2005).
122. B. Gupta and B. Ghosh, Curcuma longa inhibits TNF-alpha induced expression of adhesion molecules on human umbilical vein endothelial cells. Int J Innumopharmacol 21, 745 (1999).
123. S. M. Plummer, K. A.Holloway, M. M. Manson, R. J. Munks, A. Kaptein, S. Farrow, and L. Howells, Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 18, 6013 (1999).
124. Y. R. Chen and T. H. Tan, Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 17, 173 (1998).
125. Y. Iwakura, Roles of IL-1 in the development of rheumatoid arthritis:Consideration from mouse models. Cytokine Growth Factor Rev 13, 341 (2002).
126. N. Jurrmann, R. Brigelius-Flohe, and G. F. Bol, Curcumin blocks interleukin-1 (IL-1) signaling by inhibiting the recruitment of the IL-1 receptor-associated kinase IRAK in murine thymoma EL-4 cells. J Nutr 135, 1859 (2005).
127. G. Trinchieri, S. Pflanz, and R. A. Kastelein, The IL-12 family of heterodimeric cytokines: New players in the regulation of T cell responses.[comment]. Immunity 19, 641 (2003).
128. K. E. Balashov, D. R. Smith, S. J. Khoury, D. A. Hafler, and H. L. Weiner, Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA 94, 599 (1997).
129. J. J. Bright, M. Rodriguez, and S. Sriram, Differential influence of interleukin-12 in the pathogenesis of autoimmune and virus-induced central nervous system demyelination. J Virol 73, 1637 (1999).
130. J. P. Leonard, K. E. Waldburger, and S. J. Goldman, Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 181, 381 (1995).
131. B. Oppmann, R. Lesley, B. Blom, J. C. Timans, . Xu, B. Hunte, F. Vega, N. Yu, J. Wang, K. Singh, F. Zonin, E. Vaisberg, T. Churakova, M. Liu, D. Gorman, J. Wagner, S. Zurawski, Y. Liu, J. S. Abrams, K. W. Moore, D. Rennick, R. de Waal-Malefyt, C. Hannum, J. F. Bazan, and R. A. Kastelein, Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13, 715 (2000).
132. X. T. Ma, X. j. Zhang, B. Zhang, Y. Q. Geng, Y. M. Lin, G. Li, and K. F. Wu, Expression and regulation of interleukin-23 subunits in human peripheral blood mononuclear cells and hematopoietic cell lines in response to various inducers. Cell Biol Int 28, 689 (2004).
133. A. Wada, Y. Tada, O. Shimozato, Y. Takiguchi, K. Tatsumi, T. Kuriyama, and M. Tagawa, Expression of CD40 ligand in CD40-positive murine tumors activates transcription of the interleukin-23 subunit genes and produces antitumor responses. Anticancer Res 24, 2713 (2004).
134. D. J. Cua, J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce, B. Seymour, L. Lucian, W. To, S. Kwan, T. Churakova, S. Zurawski, M. Wiekowski, S. A. Lira, D. Gorman, R.A. Kastelein, and J. D. Sedgwick, Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.[see comment]. Nature 421, 744 (2003).
135. S. J. Szabo, S. T. Kim, G. L. Costa, X. Zhang, C. G. Fathman, and L. H. Glimcher, A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100, 655 (2000).
136. A. Takeda, S. Hamano, A. Yamanaka, T. Hanada, T. Ishibashi, T. W. Mak, A. Yoshimura, and H. Yoshida, Cutting edge: Role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol 170, 4886 (2003).
137. E. Bettelli, B. Sullivan, S. J. Szabo, R. A. Sobel, L. H. Glimcher, and V. K. Kuchroo, Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J Exp Med 200, 79 (2004).
138. A. E. Lovett-Racke, A. E. Rocchini, J. Choy, S. C. Northrop, R. Z. Hussain, R. B. Ratts, D. Sikder, and M. K. Racke, Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes. Immunity 21, 719 (2004).
139. S. Pflanz, J. C. Timans, J. Cheung, R. Rosales, H. Kanzler, J. Gilbert, L. Hibbert, T. Churakova, M. Travis, E. Vaisberg, W. M. Blumenschein, J. D. Mattson, J. L. Wagner, W. To, S. Zurawski, T. K. McClanahan, D. M. Gorman, J. F. Bazan, R. de Waal Malefyt, D. Rennick, and R. A. Kastelein, IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 16, 779 (2002).
140. R. Goldberg, Y. Zohar, G. Wildbaum, Y. Geron, G. Maor, and N. Karin, Suppression of ongoing experimental autoimmune encephalomyelitis by neutralizing the function of the p28 subunit of IL-27. J Immunol 173, 6465 (2004).
141. B. M. Segal, B. k. Dwyer, and E. M. Shevach, An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 187, 537 (1998).
142. S. Ghosh, M. J. May, and E. B. Kopp, NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16, 225 (1998).
143. G. Y. Kim, K. H. Kim, S. H. Lee, M. S. Yoon, H. J. Lee, D. O. Moon, C. M. Lee, S. C. Ahn, Y. C. Park, and Y. M. Park, Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-kappa B as potential targets. J Immunol 174, 8116 (2005).
144. G. Kang, P. J. Kong, Y. J. Yuh, S. Y. Lim, S. V. Yim, W. Chun, and S. S. Kim, Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor kappab bindings in BV2 microglial cells. J Pharmacol Sci 94, 325 (2004).
145. W. C. Sha, Regulation of immune responses by NF-kappa B/Rel transcription factor. J Exp Med 187, 143 (1998).
146. J. D. Woronicz, X. Gao, Z. Cao, M. Rothe, and D. V. Goeddel, IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. Science 278 , 866 (1997).
147. T. L. Murphy, M. G. Cleveland, P. Kulesza, J. Magram, and K. M. Murphy, Regulation of interleukin 12 p40 expression through an NF-kappa B half-site. Mol Cell Biol 15, 5258 (1995).
148. D. D'Ambrosio, M. Cippitelli, M. G. Cocciolo, D. Mazzeo, P. Di Lucia, R. Lang, F. Sinigaglia, and P. Panina-Bordignon, Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 101, 252 (1998).
149. D. Mazzeo, P. Panina-Bordignon, H. Recalde, F. Sinigaglia, and D. D'Ambrosio, Decreased IL-12 production and Th1 cell development by acetyl salicylic acid-mediated inhibition of NF-kappaB. Eur J Immunol 28, 3205 (1998).
150. C. M. Bacon, E. F. Petricoin 3rd, J. R. Ortaldo, R. C. Rees, A. C. Larner, J. A. Johnston, and J. J. O'Shea, Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. Proc Natl Acad Sci USA 92, 7307 (1995).
151. N. G. Jacobson, S. J. Szabo, R. M. Weber-Nordt, Z. Zhong, R. D. Schreiber, J. E. Darnell, Jr., and K. M. Murphy, Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. J Exp Med 181, 1755 (1995).
152. C. Parham, M. Chirica, J. Timans, E. Vaisberg, M. Travis, J. Cheung, S. Pflanz, R. Zhang, K. P. Singh, F. Vega, W. To, J. Wagner, A. M. O'Farrell, T. McClanahan, S. Zurawski, C. Hannum, D. Gorman, D. M. Rennick, R. A. Kastelein, R. deWaal Malefyt, and K. W. Moore, A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 168, 5699 (2002).
153. S. Aggarwal, N. Ghilardi, M. H. Xie, F. J. de Sauvage, and A. L. Gurney, Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278, 1910 (2003).
154. S. Kamiya, T. Owaki, N. Morishima, F. Fukai, J. Mizuguchi, and T. Yoshimoto, An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells. J Immunol 173, 3871 (2004).
155. J. J. O'Shea, H. Park, M. Pesu, D. Borie, and P. Changelian, New strategies for immunosuppression, interfering with cytokines by targeting the Jak/Stat pathway. Curr Opin Rheumatol 17, 305 (2005).
156. H. M. Seidel, P. Lamb, and J. Rosen, Pharmaceutical intervention in the JAK/STAT signaling pathway. Oncogene 19, 2645 (2000).
157. J. J. Bright, Targeting autoimmune diseases through nutraceuticals. Nutrition 20, 39 (2004).
158. G. Muthian and J. J. Bright, Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte. J Clin Immunol 24, 542 (2004).
159. G. Muthian, H. P. Raikwar, J. Rajasingh, and J. J. Bright, 1,25 Dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFNgamma axis leading to Th1 response in experimental allergic encephalomyelitis. J Neurosci Res 83, 1299 (2006).
160. L. Neff, M. Zeisel, J. Sibilia, M. Scholler-Guinard, J. P. Klein, and D. Wachsmann, NF-kappaB and the MAP kinases/AP-1 pathways are both involved in interleukin-6 and interleukin-8 expression in fibroblast-like synoviocytes stimulated by protein I/II, a modulin from oral streptococci. Cell Microbiol 3, 703 (2001).
161. R. K. Patel and C. Mohan, PI3K/AKT signaling and systemic autoimmunity. Immunol Res 31, 47 (2005).
162. J. W. Cho, K. Park, G. R. Kweon, B. C. Jang, W. K. Baek, M. H. Suh, C. W. Kim, K. S. Lee, and S. I. Suh, Curcumin inhibits the expression of COX-2 in UVB-irradiated human keratinocytes (HaCaT) by inhibiting activation of AP-1, p38 MAP kinase and JNK as potential upstream targets. Exp Mol Med 37 , 186 (2005).
163. S. L. Kunkel and N. Godessart, Chemokines in autoimmunity: From pathology to therapeutics. Autoimmun Rev 1, 313 (2002).
164. S. Arimilli, W. Ferlin, N. Solvason, S. Deshpande, M. Howard, and S. Mocci, Chemokines in autoimmune diseases. Immunol Rev 177, 43 (2000).
165. X. Chen, J. J. Oppenheim, and O. M. Howard, Chemokines and chemokine receptors as novel therapeutic targets in rheumatoid arthritis (RA): Inhibitory effects of traditional Chinese medicinal components. Cell Mol Immunol 1, 336 (2004).
166. H. Hidaka, T. Ishiko, T. Furuhashi, H. Kamohara, S. Suzuki, M. Miyazaki, O. Ikeda, S. Mita, T. Setoguchi, and M. Ogawa, Curcumin inhibits interleukin 8 production and enhances interleukin 8 receptor expression on the cell surface: Impact on human pancreatic carcinoma cell growth by autocrine regulation. Cancer 95, 1206 (2002).